Fasting Blood Sugar (FBS)
Sources
Fasting Blood Sugar (FBS)
Longitudinal Data
| Date | Value | Flag | Context/Notes | Source |
|---|---|---|---|---|
| 2022-11-25 | 68 | N | JDC Lab (Jothydev's) — GOD-PAP method. Ref 60–110 mg/dL. Fasting. Dr. Arun Shankar. On Tresiba (insulin) + Trajenta + Glucoformin. | raw/assets/20260429_IMG_9753.jpeg |
Trend Analysis
One data point available. FBS 68 mg/dL (normal, 60-110) on 2022-11-25 — within the normal fasting range for the JDC laboratory. This measurement was taken in the context of:
- Patient on full anti-diabetic regimen: insulin (Tresiba 10 units), Trajenta 5 mg (DPP-4 inhibitor), Glucoformin XL 500 mg TID (metformin)
- Concurrent HbA1c 5.8% (pre-diabetic per facility's reference of <5.7%)
- Patient's fasting glucose was controlled on this medicated state
[!note] Interpretation Context
A fasting glucose of 68 mg/dL while on insulin + metformin + Trajenta does not indicate excellent natural glucose control — it reflects pharmacological management. The concurrent HbA1c of 5.8% (in pre-diabetic range at that time) was consistent with this level of treated control.By contrast, the Apr 2026 fructosamine of 310 µmol/L (HIGH) — obtained without documented anti-diabetic medications — indicates deterioration in glycemic control in the period since 2022, likely compounded by AML and its treatment.
Related Pages
- Hba1C — Concurrent HbA1c 5.8% (Nov 2022)
- Fructosamine — Most recent glycemic marker (Apr 2026, HIGH)
- Diabetes Mellitus — Underlying condition
Source: raw/assets/20260429_IMG_9753.jpeg